# Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

> **NCT04891237** · PHASE3 · RECRUITING · sponsor: **Inmunotek S.L.** · enrollment: 180 (estimated)

## Conditions studied

- Rhinitis, Allergic
- Rhinoconjunctivitis
- Asthma, Allergic

## Interventions

- **BIOLOGICAL:** 10,000 MG01 + 10,000 T517
- **BIOLOGICAL:** 30,000 MG01 + 10,000 T517
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04891237
- **Lead sponsor:** Inmunotek S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-14
- **Primary completion:** 2026-01
- **Final completion:** 2027-01
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04891237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04891237, "Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04891237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*